Nephrologie & therapeutique · 2011
[Association of post-transplant lymphoproliferative disease and visceral leishmaniasis after kidney transplantation].
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bacha Mohamed Mongi, Abderrahim Ezzeddine, Ounissi Mondher, Chaouech Dalel, Cherif Mejda, Turki Sami, Rajhi Hatem, Znaidi Nadia, Bahloul Abdessalem, Trabelsi Sonia, Khaled Samira, Ben Abdallah Taïeb, Ben Maïz Hedi, Kheder Adel
Аннотация
Malignancies and opportunistic infections are frequently observed after solid-organ transplantation. Their occurrence strongly affects recipient survival. We report the case of a 29-year-old Tunisian kidney-recipient who was diagnosed simultaneously with post-transplant lymphoproliferative disease (PTLD) and visceral leishmaniasis (VL). Withdrawal of immunosuppressive therapy together with antiparasitic treatment using liposomal amphotericin B, and anti-CD20 antibodies medication resulted in cure of leishmaniasis and remission from PTLD. This case is of clinical interest because of the uncommon association of VL with PTLD after solid organ transplantation. It is also original by the favourable outcome of VL and PTLD, both known as life-threatening diseases. Also, it illustrates the predisposing role of immunosuppressive therapy in occurrence of opportunistic infections and malignancies after solid organ transplantation.
Предметные рубрики MeSH
AdultAmphotericin BAntibodies, Monoclonal, Murine-DerivedAntiprotozoal AgentsAntiviral AgentsEpstein-Barr Virus InfectionsGanciclovirHumansImmunocompromised HostImmunosuppressive AgentsKidney TransplantationLeishmaniasis, VisceralLymphoproliferative DisordersMaleMeglumineMeglumine AntimoniateOpportunistic InfectionsOrganometallic CompoundsPostoperative ComplicationsRemission InductionRituximabSirolimus